News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II (World)
Braeburn Pharma Release: Phase II Trial Demonstrates Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder 6/23/2017
Bellicum (BLCM) Announces Clinical Data On BPX-501 At Presidential Symposium Of The 22nd Congress Of The European Hematology Association 6/23/2017
Bellicum (BLCM) Reports Clinical Results Of BPX-501 In Pediatric Leukemias At The 22nd Congress Of The European Hematology Association 6/23/2017
Hutchison China MediTech (Chi-Med) Initiates A Phase I/II Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In China 6/22/2017
Zealand Pharma  (ZEAL.CO) Release: Phase IIa Trial Results Support Development Of Dasiglucagon In The ILet Pump System For Type 1 Diabetes 6/22/2017
Herantis Pharma's Lymfactin Study Advances To Last Patient Cohort, Company Announces Initial Plans For Continued Development 6/22/2017
InDex Pharmaceuticals AB Enrolls First Patient In The Phase IIb Study CONDUCT With Cobitolimod 6/21/2017
Kadimastem Received Approval From The Hadassah Hospital IRB (Helsinki Committee) For Conducting A Clinical Trial In ALS Patients 6/21/2017
ErgoMed Release: PeproStat Phase IIb Study Passes Recruitment Mid-Point Ahead Of Schedule 6/21/2017
Ipsen (IPN.PA) And Its Partner Exelixis (EXEL) Announce Independent Radiology Committee Review Confirms Results From Phase II CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma 6/20/2017
Galapagos (GLPG.BR)' R&D Update 2017: Rapidly Advancing Our Product Candidates 6/20/2017
Neovacs Announces The Completion Of Patient Enrollment In Phase IIb Clinical Study Of IFNalpha Kinoid In Lupus 6/20/2017
Galapagos (GLPG.BR)' R&D Update 2017: Rapidly Advancing Our Product Candidates 6/20/2017
GeNeuro Announces First Patient Treated In Phase IIa Study With Gnbac1 In Type 1 Diabetes 6/19/2017
Genexine Co. Ltd. Receives Approval To Initiate Phase Ib/II Trial Of GX-188E, HPV Therapeutic DNA Vaccine, In Combination With KEYTRUDA (Pembrolizumab), For The Treatment Of HPV-Induced Cervical Cancer 6/19/2017
Zealand Pharma  (ZEAL.CO) Release: Glepaglutide Meets Primary Endpoint In Phase II Trial In Patients With Short Bowel Syndrome 6/19/2017
VBL Therapeutics (VBLX) Provides Update On Long-Term Survival In Phase II Trials Of Patients With Multiple Tumor Types 6/19/2017
Why Drug Giants Like Merck & Co. (MRK) and AstraZeneca PLC (AZN) Scientists are Looking in the Toilet for New Cancer Treatments 6/16/2017
MediWound (MDWD) Release: IIndependent Study In Germany Shows NexoBrid Reduces Average Burn Treatment Costs By Nearly 30% Versus Standard Of Care 6/16/2017
Mallinckrodt (MNK) Enrolls First Patient In Phase IIB Trial Of H.P. Acthar Gel (Repository Corticotropin Injection) For Amyotrophic Lateral Sclerosis (ALS) 6/15/2017
Debiopharm Announces Completion Of Enrollment In Phase I/II Clinical Trial With Debio 1143 In SCCHN 6/15/2017
Modra Pharma Announces Start Of Phase II Study For Its Lead Oral Chemotherapy In Patients With Metastatic Prostate Cancer 6/14/2017
GenSight Reports Long-Term Positive Safety And Visual Acuity Results At Week 96 In Phase I/II Study Of GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON) 6/14/2017
Janssen Pharmaceutical Release: Pimodivir Alone Or In Combination With Oseltamivir Demonstrated A Significant Reduction In Viral Load In Adults With Influenza A 6/14/2017
SoCal's Regulus (RGLS) Sinks After AstraZeneca PLC (AZN) Bails on Lead NASH Drug 6/13/2017
Probiodrug AG Announces Encouraging Results Of The Phase IIa SAPHIR Study 6/12/2017
Sophiris Bio (SPHS) Announces That The First Patient Has Been Dosed In Phase IIb Study Of Topsalysin In Patients With Clinically Significant Localized Prostate Cancer 6/8/2017
NovoCure Release: First Patient Enrolled In RTOG Trial Of Optune Together With Bevacizumab For Patients With Bevacizumab-Refractory Recurrent Glioblastoma 6/8/2017
Novartis AG (NVS) Finally Reveals Long-Awaited JULIET CAR-T Data 6/7/2017
Kamada Ltd. (KMDA) Provides Update On Clinical Program For Alpha-1 Antitrypsin IV For Treatment Of Graft-Versus-Host Disease 6/7/2017
Poxel (POXEL.PA) Announces Additional Positive Results For Imeglimin Phase IIb Study In Japan For The Treatment Of Type 2 Diabetes 6/6/2017
MorphoSys AG Presents First Safety And Efficacy Data Of MOR208 In Combination With Lenalidomide From A Phase II Study In DLBCL 6/6/2017
Bristol-Myers Squibb (BMY) Release: Encouraging Disease Control Rates Observed With Nivolumab Alone Or In Combination With Ipilimumab In Refractory Or Relapsing Malignant Pleural Mesothelioma Patients: Results From IFCT-1501 MAPS-2 Trial 6/5/2017
Helsinn And MEI Pharma (MEIP) Report Correlation Between Mutations In DNA Methylation Pathway And Clinical Response In Phase II Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia 6/5/2017
Positive Phase IIb Trial Of Pharmalink AB's Nefecon In Primary IgA Nephropathy Presented At Leading Kidney Disease Conference 6/5/2017
NeuroDerm (NDRM) Presents ND0612H Phase II Trial Results In Late-Breaking Poster Session At The 21st International Congress Of Parkinson’s Disease And Movement Disorders 6/5/2017
HalioDx Highlights Use Of Immunosign To Define CAR T-Cell Therapy Signature In Tumor At ASCO 2017 6/5/2017
Aurinia (AUPH) Presents Additional Data From Phase IIb AURA-LV Study, Demonstrating Stable Renal Function And Blood Pressure Without Electrolyte Complications Through 48 Weeks 6/5/2017
Novartis AG (NVS) Landmark Study Of Tafinlar + Mekinist Demonstrates Durable Survival Benefit At Five Years In Patients With BRAF Mutation-Positive Metastatic Melanoma 6/5/2017
Medical Prognosis Institute - The Efficacy Of Chemotherapy With Epirubicin, One The Of Most Used Drugs In Breast Cancer Can Now Be Predicted By DRP - Poster Published At ASCO 6/5/2017
Prima Biomed (PRR.AX) Release: LAG-3Ig (IMP321) Demonstrates Positive Safety And Efficacy Qualities In Breast Cancer Clinical Trial 6/5/2017
Eisai Company (ESALY.PK) To Present Results Of Phase Ib/II Study Of Anticancer Agent Lenvima (Lenvatinib) In Combination With Anti-PD-1 Antibody Pembrolizumab 6/5/2017
MorphoSys AG Presents Updated Clinical Data For Anti-CD38 Antibody MOR202 In Multiple Myeloma At ASCO 2017 6/5/2017
Vaxon Biotech SA Announces Results Of Its Phase IIb Lung Cancer Trial Of Vx-001, A Therapeutic Vaccine Based On Optimized Cryptic Peptides 6/1/2017
Hepatera: Eligibility To PRIME Scheme Granted To Myrcludex B By The EMA 5/25/2017
6 (Plus 2!) Most Notable ASCO Abstracts So Far 5/24/2017
Kamada Ltd. (KMDA) Presents Updated Data From Phase II Clinical Trial Of Inhaled Alpha-1-Antitrypsin For Treatment Of Alpha-1 Antitrypsin Deficiency At 2017 American Thoracic Society International Conference 5/24/2017
ORYX Reports Positive Clinical Evidence With Oncolytic Virus ParvOryx In Combination With Immuno-Oncology Drugs 5/23/2017
NeuroDerm (NDRM) ND0612H Phase II Trial Results To Be Presented In Late-Breaking Session At The 21st International Congress Of Parkinson’s Disease And Movement Disorders 5/23/2017
Protalix (PLX) Announces Presentation Of Phase II Clinical Trial Results For Alidornase Alfa In Cystic Fibrosis At The 40th European Cystic Fibrosis Society Conference 5/23/2017
Zealand Pharma  (ZEAL.CO) Release: Positive Phase IIa Results With Microdoses Of Dasiglucagon Support Use In A Dual-Hormone Artificial Pancreas System 5/23/2017
AM-Pharma Completes Patient Recruitment Of Recombinant Human Alkaline Phosphatase (recAP) Phase II Trial In Acute Kidney Injury 5/22/2017
Myovant (MYOV) Announces Presentation Of Positive Phase II Data For Relugolix In Women With Endometriosis-Associated Pain At The World Congress On Endometriosis 5/22/2017
Polyphor Announces Successful End Of Phase II Meeting With FDA For Murepavadin In Nosocomial Pneumonia 5/19/2017
Astellas (ALPMY) Announces Oncology Portfolio Updates 5/18/2017
The Lancet Publishes Phase ll Results From Shire (SHPG)'s Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates In Patients With Moderate-To-Severe Ulcerative Colitis 5/18/2017
Data From Prima Biomed (PRR.AX) AIPAC Clinical Trial To Be Presented At 2017 ASCO Conference 5/18/2017
Nanobiotix Announces First Positive Human Data Showing That NBTXR3 Could Become A Backbone In Immuno-Oncology 5/18/2017
Galapagos (GLPG.BR) Release: Seven Abstracts On Filgotinib Accepted By EULAR 2017 5/16/2017
NOXXON Pharma AG Announces Collaboration With National Center For Tumor Diseases In Heidelberg For Nox-A12/Keytruda Phase I/II Combination Trial 5/16/2017
Inventiva Announces Positive Results Of 12 Month Primate Toxicity Study With IVA337 5/16/2017
Summit Therapeutics Completes Enrollment Of Phaseout DMD, A Phase II Clinical Trial Of Ezutromid In Patients With DMD 5/15/2017
Antibe Therapeutics (ATE.V) Engages Topstone Research And Appoints Dr Francis Chan As Key Advisor For Phase II Clinical Trial Of ATB-346 5/12/2017
4 Biotechs That Could Release Stock-Shattering Data Soon 5/11/2017
Biophytis: First Patient-In In The United States And Opening Of 2 Clinical Centers For The SARA-OBS Study On Sarcopenia 5/11/2017
Oncoquest Announces Enrollment Of First Patient In Phase I/II Clinical Study Using Combination Of Oregovomab With Checkpoint Inhibitor Nivolumab In Recurrent Ovarian Cancer 5/9/2017
AiCuris Initiates U.S. Clinical Phase II Trial With Oral Pritelivir For The Treatment Of HSV Infections In Immunocompromised Adults 5/9/2017
Eyevensys Announces The First-In-Human Treatment With Its GroundBreaking EyeCET ElectroTransfection Technology For Eye Diseases 5/9/2017
Myovant (MYOV) Announces Presentation Of Positive Phase II Data For Relugolix In Women With Heavy Menstrual Bleeding And Uterine Fibroids At The Annual Meeting Of The American Congress Of Obstetricians And Gynecologists 5/8/2017
DelMar Pharma Presents New Mechanism Of Action Data For Its Lead Agent VAL-083 In Temozolomide-Resistant Glioblastoma Multiforme (GBM) At The World Federation Of Neuro-Oncology Societies (WFNOS) 5/8/2017
Galapagos (GLPG.BR) Presents Three Posters On Filgotinib In Crohn's Disease At DDW 2017 5/8/2017
4 Biotechs That Could Explode Or Crash In May 5/5/2017
First Patient Enrolled In Mallinckrodt (MNK) Phase II Trial Of StrataGraft Regenerative Skin Tissue 5/5/2017
GENFIT (ALGFT): First Patient Enrolled In A Phase II Trial Recruiting Adults With Primary Biliary Cholangitis (PBC), A Rare Liver Disease 5/5/2017
GENFIT (ALGFT): First Patient Enrolled In A Phase II Trial Recruiting Adults With Primary Biliary Cholangitis (PBC), A Rare Liver Disease 5/5/2017
Poxel (POXEL.PA) Rockets After Diabetes Med Hits Goals In Mid-Stage Study 5/4/2017
Neovacs To Present Clinical Development Update On IFNa Kinoid in Dermatomyositis 5/4/2017
Argenx Reaches 50% Enrollment In Phase II Clinical Trial Of ARGX-113 In Myasthenia Gravis 5/4/2017
GenKyoTex S.A. Announces FDA Approval Of IND For Phase II Trial Of GKT831 In Patients With Primary Biliary Cholangitis 5/3/2017
Abivax (ABVX.PA) Stock More Than Doubles On Mid-Stage HIV Data 5/2/2017
Phase II CoDIFy Trial Results Published In Lancet Infectious Diseases With Data Showing Summit Therapeutics’s Ridinilazole Achieved Statistical Superiority Over Vancomycin In The Treatment Of C. Difficile Infection 5/2/2017
First Ever Evidence Of Treatment-Induced Reduction In HIV Reservoirs:Abx464, Abivax (ABVX.PA) Lead Drug Candidate, Impacted Hiv Blood Reservoir In A Phase IIa Clinical Trial (Abx464-004) 5/2/2017
Summit Therapeutics: Phase II CoDIFy Trial Results Published In Lancet Infectious Diseases 5/2/2017
Living Cell Tech Release: Treatment Completed For All Patients In Parkinson’s Trial 5/1/2017
PIQUR Therapeutics AG Receives EMA Orphan Drug Designation For PQR309 In Diffuse Large B-Cell Lymphoma 4/27/2017
Wilson Therapeutics Presents Promising Neurological Phase 2 Data For WTX101 At American Academy of Neurology Meeting 4/26/2017
Galapagos (GLPG.BR) Announces New Phase II Proof-Of-Concept Study With Filgotinib In Cutaneous Lupus Erythematosus 4/26/2017
Vyome Completes Enrollment For Proof Of Concept Clinical Study Of VB 1953 In Patients With Moderate To Severe Acne 4/25/2017
ASLAN Initiates Global Pivotal Study For Varlitinib In Biliary Tract Cancer 4/25/2017
Blueberry Therapeutics Commence Phase I/II Clinical Trial Of Lead Product BB2603 4/25/2017
Finally! Novartis AG (NVS) To Release Long-Awaited Juliet CAR-T Data In June 4/25/2017
Top 15 R&D Spenders In The World For 2017 4/24/2017
Tiziana Life Sciences Plc Announces Approval Of A Phase II Clinical Trial Protocol For Milciclib In Patients With Hepatocellular Carcinoma 4/24/2017
NGM Announces NGM282 Dramatically Reduced Liver Fat And Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) In Phase II Trial 4/24/2017
Shionogi Presents New Clinical And Non-Clinical Data On S-033188, An Investigational Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza, At The 27th European Congress Of Clinical Microbiology And Infectious Diseases 4/24/2017
Mologen (MOLGF.PK): Positive Subgroup Results Of The Exploratory Phase II IMPULSE Study Of Lefitolimod In Extensive-Disease Small-Cell Lung Cancer (SCLC) 4/24/2017
Akari Therapeutics Demonstrates Positive Response With Coversin In Ongoing Phase II PNH Trial And In Additional Clinical Targets 4/24/2017
Wilson Therapeutics Presented Positive Final Phase II Data For WTX101 At EASL Annual Meeting 4/24/2017
RedHill Biopharma (RDHL) Announces Enrollment Of Last Patient In The BEKINDA Phase II Study For IBS-D 4/24/2017
Aurinia (AUPH) Releases Additional 48-Week Data From The AURA-LV Study During Late-Breaking Session At National Kidney Foundation 2017 Spring Clinical Meetings 4/21/2017
BeiGene (BGNE) Announces Initiation Of First Pivotal Study In China Of PD-1 Antibody BGB-A317 4/21/2017
Laurent Receives FDA And Health Canada Clearance To Initiate APPLAUD Phase II Clinical Study Of LAU-7b For The Treatment Of Cystic Fibrosis 4/19/2017
RedHill Biopharma (RDHL) To Host R&D Day On BEKINDA For Acute Gastroenteritis And IBS-D 4/19/2017
GeNeuro Initiates Phase IIa Study With Gnbac1 In Type 1 Diabetes In Australia 4/19/2017
Shionogi Presents New Data On Cefiderocol (S-649266), A Siderophore Cephalosporin, And S-033188 A Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza At ECCMID 2017 4/18/2017
Circassia (CIR.L) Finally Throws In The Towel On Allergy Program After Trial Failures 4/18/2017
Protalix Biotherapeutics, Inc. (PLX) Announces Positive Results From Phase II Clinical Trial Of Alidornase Alfa (AIR Dnase) For The Treatment Of Cystic Fibrosis 4/12/2017
Argenx Launches Phase II Study Of ARGX-110 As A Monotherapy In Relapsed/Refractory CTCL Patients 4/12/2017
TRANSGENE (ENX:TNG) And Institut Bergonié Start The Phase II Part Of METROmaJX Trial 4/12/2017
3 Drug Giants That Boasts the Best Pipelines 4/11/2017
Inventiva Hits Clinical Milestone With Enrollment Of 100th Patient In IVA337 Phase IIb FASST Trial In Systemic Sclerosis (SSc) 4/10/2017
Medivir (MVRBF) Announces Positive Data From The Phase II Study Of Remetinostat In Patients With Early-Stage Cutaneous T-Cell Lymphoma 4/7/2017
Probiodrug AG Release: Last Patient Last Visit (LPLV) Reached In The SAPHIR Study 4/7/2017
Despite a Mixed PhII, Allergan (AGN) Charges Toward a Late-Stage Depression Study for Botox 4/6/2017
Oncolytics Biotech (ONC.TO)’s REOLYSIN More Than Doubles Overall Survival in Patients With Mutated p53 Metastatic Breast Cancer 4/5/2017
MediGene AG (MDGEF.PK): Academic Partner Presented Compassionate Use Data On AML DC Vaccine At AACR Conference 4/5/2017
ASIT Biotech Announces That It Has Achieved The Primary Endpoint Of The Phase I/IIa Clinical Trial With Its hdm-ASIT+ Product Candidate For House Dust Mite Rhinitis 4/5/2017
Journal Of Diabetes Science And Technology Publishes Scientific Paper Authored By Oramed (ORMP) Scientists 4/4/2017
Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Completion Of Recruitment For Phase IIb Clinical Trials Of Myrcludex B In Chronic Hepatitis Delta 4/4/2017
Galapagos (GLPG.BR) Announces Three New Phase II Proof-Of-Concept Studies With Filgotinib 4/4/2017
Nanobiotix Expands Its Clinical Development In Head And Neck Cancer And I/O 4/4/2017
NovoCure Enrolls Last Patient In STELLAR Trial Testing Tumor Treating Fields In Combination With Standard Of Care Chemotherapy In Mesothelioma 3/31/2017
Akari Therapeutics Announces FDA Fast Track Designation For Coversin 3/31/2017
Opthea Conference Call/Webcast -- Update On OPT-302 Phase 1/2A Wet AMD Clinical Trial 3/31/2017
Johnson & Johnson (JNJ) Stops Mid-Stage Trial For Genmab A/S (GEN.CO)'s Blood Cancer Drug Due To Futility 3/31/2017
Takeda (TKPYY)’s Dengue Vaccine Candidate Elicited Broad Immune Responses In Children And Adolescents Living In Dengue-Endemic Areas; Interim Phase 2 Analysis Published In The Lancet Infectious Diseases 3/30/2017
Avillion Signs Clinical Co-Development Agreement With Merck & Co. (MRK) To Advance Anti IL-17 A/F Nanobody In Psoriasis 3/30/2017
Araclon Biotech Selects MedAvante Virgil Platform For Phase II Alzheimer's Trial 3/30/2017
Positive Results Of Phase IIb Clinical Trial Of Pharmalink AB's Nefecon In Primary IgA Nephropathy Published In The Lancet 3/29/2017
Clementia Release: Phase II Part A Open Label Extension Trial Of Palovarotene For Treatment Of Patients With Fibrodysplasia Ossificans Progressiva Continues Positive Trends 3/28/2017
RXi Pharma (RXII) Granted Patent In Japan For Lead Clinical Candidate RXI-109 3/28/2017
Aurinia (AUPH) Highlights 48-Week Data From Open-Label AURION Study At 12th International Congress On SLE (LUPUS 2017) & The 7th Asian Congress On Autoimmunity (ACA 2017) 3/27/2017
ERYtech Pharma Reports Positive Phase IIb Data For Eryaspase For The Treatment Of Metastatic Pancreatic Cancer 3/27/2017
Xenon Pharmaceuticals Inc. Dumps Acne Drug After Trial Failure 3/24/2017
Why Struggling Bristol-Myers Squibb (BMY) Could Take Out This Danish Biotech in Major €500M Deal 3/23/2017
Novartis AG (NVS)'s Phase III Drug for Heart Failure Bombs Trial 3/23/2017
Poxel SAS Announces Positive Results For Thorough QT Safety Clinical Study Of Imeglimin 3/21/2017
NETRIS Pharma Starts Enrollment Of First Clinical Study To Evaluate Drug Candidate Targeting Dependence Receptors 3/21/2017
NightstaRx Commences First Phase I/II Gene Therapy Clinical Trial For Patients With X-Linked Retinitis Pigmentosa 3/20/2017
BioLineRx Provides Update On Phase II Open-Label Study For BL-8040 As Novel Stem Cell Mobilization Treatment 3/20/2017
BioLineRx Provides Update On Phase 2 Open-Label Study For BL-8040 As Novel Stem Cell Mobilization Treatment 3/20/2017
Major Achievements In 2016 Validate TRANSGENE (ENX:TNG)’s Strategy And Provide Promising Outlook For 2017 3/20/2017
Selvita Announces First Patient Dosed In Phase I/II Clinical Trial Of SEL24 In Acute Myeloid Leukemia 3/17/2017
Karolinska Development AB Umecrine Cognition Announces First Patient Included In Clinical Phase Ib/IIa Study With GR3027 For Hepatic Encephalopathy 3/17/2017
Cytuvax Starts Its Phase II BE RESPONDER! Study Effective Vaccination For Hepatitis B Non-Responders 3/14/2017
MetrioPharm AG Announces Positive Top-Line Results From A Phase IIa Study In Moderate-To-Severe Psoriasis With Its Oral Lead Compound MP1032 3/14/2017
Sanofi (SNY) And Voluntis Announce A Global Alliance To Deliver Digital Insulin Titration Solutions For People With Type II Diabetes 3/14/2017
Kiadis Pharma To Present Atir10 Phase II Trial Data In Late Breaking Abstract At The International Society For Cellular Therapy (ISCT) 2017 Annual Meeting 3/13/2017
TiGenix Announces Top-Line Phase I/II Results Of AlloCSC-01 In Acute Myocardial Infarction 3/13/2017
Selvita To Present New Data From Its Oncology Programs At The Upcoming AACR Annual Meeting 2017 3/13/2017
First Patient Dosed In Phase 2 Trial Evaluating TRANSGENE (ENX:TNG)’s TG4010 In Combination With Opdivo (Nivolumab) For 2nd Line Treatment Of Metastatic Non-Small Cell Lung Cancer (NSCLC) 3/13/2017
Nature Cell Started Commercial Clinical Trials Phase I And II "ASTROSTEM," Stem Cell Drug For Alzheimer's Disease Treatment In U.S. 3/10/2017
REGiMMUNE Phase IIa Results Of RGI-2001, An Activator Of Invariant Natural Killer T Cells, Published In "Biology Of Blood And Marrow Transplantation" 3/10/2017
Galapagos (GLPG.BR) Release: New Phase II Studies With Filgotinib In Small Bowel And Fistulizing Crohn's Disease 3/10/2017
Bone Therapeutics Completes Recruitment Of 16 Patients In ALLOB Phase I/IIA Delayed-Union Study 3/9/2017
Menlo Therapeutics Announces Successful Pruritus Reduction Results From Phase 2 Serlopitant Trial (TCP-102) In 127 Subjects With Prurigo Nodularis 3/8/2017
Neurim Pharmaceuticals Release: Phase II Clinical Trial For Treatment Of Mild Alzheimer's Disease 3/7/2017
Aurinia (AUPH) Announces Acceptance Of Voclosporin Late-Breaking Presentation At National Kidney Foundation 2017 Spring Clinical Meetings 3/7/2017
Aurinia (AUPH) Announces Acceptance Of Voclosporin Late-Breaking Presentation At National Kidney Foundation 2017 Spring Clinical Meetings 3/7/2017
Abzena Inside Product For Neurodegenerative Conditions Moves Into Phase II Trial 3/6/2017
Kamada Ltd. (KMDA) To Host R&D Day Focused On Graft Versus Host Disease (GvHD) 3/3/2017
LEO Pharma Announces Positive Results From Phase 2b Clinical Study For Tralokinumab In Atopic Dermatitis 3/3/2017
Chugai Pharma's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "Nemolizumab (CIM331)" Global Phase II Study Data Published In The New England Journal of Medicine Online 3/2/2017
SELLAS Life Sci Announces Updated Positive Phase II Data Reinforcing Meaningful Clinical Benefit Of Its WT1 Immunotherapeutic Anti-Cancer Treatment In Multiple Myeloma Patients 3/1/2017
NeuroDerm (NDRM) Achieves Primary Endpoint In ND0612H Phase II Trial For Advanced Parkinson’s Disease; Seeks Broader EU Label Based On Indigo Trial Following EMA Meeting 3/1/2017
Roche (RHHBY)'s Renal Success Spells Danger For All-Comer Studies 2/27/2017
Addex Therapeutics (ADXN.SW)'s ADX71149 Anti-Epileptic Effect Highlighted In Scientific Journal, Epilepsia 2/27/2017
Resverlogix (RVX.TO) Reports Positive FDA Type B Meeting On Design Issues Relating To A Proposed Phase IIa Kidney Dialysis Trial 2/23/2017
Minoryx Therapeutics Receives Orphan Drug Designation From The FDA For Its Lead Candidate MIN-102 2/22/2017
Immuron Completes Phase II NASH Clinical Trial Recruitment 2/21/2017
Cell Medica: Lead Cancer Immunotherapy Candidate Receives FDA Fast Track Designation 2/21/2017
OncoGenex (OGXI) Announces Phase II Apatorsen Data For Two Clinical Trials Presented At The OncoGenex (OGXI) 2017 Genitourinary Cancers Symposium 2/21/2017
Apitope Announces Positive ATX-MS-1467 Phase IIa Data In Relapsing Multiple Sclerosis 2/21/2017
Apitope Announces Positive ATX-MS-1467 Phase IIa Data In Relapsing Multiple Sclerosis 2/21/2017
Hutchison China MediTech (Chi-Med) Initiates A Phase II Study Of Savolitinib In Pulmonary Sarcomatoid Carcinoma 2/20/2017
Could Marijuana Be the Next Miracle Drug For Treating Cancer? 2/20/2017
ASLAN Receives Orphan Drug Designation In Korea For Varlitinib (ASLAN001) In Biliary Tract Cancer 2/20/2017
Ascendis Announces Publication Of Comprehensive Results From Randomized, Active-Controlled Phase 2 Trial Of Once-Weekly Transcon Growth Hormone In Pediatric Patients 2/17/2017
Hutchison China MediTech (Chi-Med): Savolitinib PRCC Results Presentation At ASCO GU 2/14/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters 2/14/2017
Biotron Limited (BIT:AU) Release: Commencement Of BIT225 Phase ll HIV-1 Clinical Trial 2/13/2017
MMJ PhytoTech Phase ll Clinical Trial For Treatment of Epilepsy Underway 2/13/2017
Boehringer Ingelheim Release: Afatinib To Be Evaluated In Combination With PD-1 Inhibitor Pembrolizumab In New Trial For Patients With Squamous Cell Carcinoma Of The Lung 2/9/2017
CRT Pioneer Fund And Cardiff University Announce The Initiation Of The Phase II MONOCLE Study Of Tefinostat For The Treatment Of Chronic Myelomonocytic Leukaemia With Funding To Progress Further Development 2/8/2017
GlaxoSmithKline (GSK)'s Incoming CEO Preps for Deals, R&D Decisions on New Drugs 2/7/2017
Immuron Announces First Patient Enrolled In Pediatric Fatty-Liver Phase II Trial 2/7/2017
Another Letdown for Bristol-Myers Squibb (BMY) as Partner Innate Pharma (IPH.PA )'s Leukemia Candidate Flunks Phase II Test 2/6/2017
Zealand Pharma  (ZEAL.CO) Release: Patient Recruitment Completed For Phase II Trial With Glepaglutide For Treatment Of Short Bowel Syndrome 2/6/2017
DBV Tech Announces Completion Of Enrollment Of Phase IIA Study Of Viaskin Milk For The Treatment Of Pediatric Eosinophilic Esophagitis 2/3/2017
Galapagos (GLPG.BR) Doses First Patient With Novel CF Corrector GLPG2222 2/2/2017
Medivir (MVRBF) Release: MIV-711 Osteoarthritis Trial: Successful Fourth Independent Review Of Safety Data Enables Trial Continuation Without Any Modifications 2/1/2017
TiGenix Enrolls First Patient iIn Phase Ib/IIa Clinical Trial Of Cx611 In Severe Sepsis 1/31/2017
Scientists Highlight the Hopes and Fears of Cellectis (ALCLS)' CAR-T 1/26/2017
Biomay AG Release: Company Reports Positive Results From A Second Phase Ilb Trial With The Innovative 3rd Generation Grass Pollen Allergy Vaccine Bm32 1/26/2017
4SC (VSC.F) Release: Overall Survival Benefit For Resminostat In First-Line Liver Cancer Study Subgroup 1/26/2017
Novartis AG (NVS) Shows Off 13 Potential Blockbusters in Pipeline 1/25/2017
DelMar Pharma Release: Company And MD Anderson Cancer Center Initiate New Phase Two Clinical Trial Of VAL-083 For MGMT-Unmethylated Recurrent Glioblastoma Multiforme (GBM) 1/25/2017
ProMetic Life Sci (PFSCF.PK) Release: Company's PBI-4050 Receives Promising Innovative Medicine Designation From The UK MHRA For The Treatment Of Alström Syndrome 1/24/2017
Genmab A/S (GEN.CO) Release: Company Provides Clinical And Regulatory Update For NCX 470 For IOP Lowering 1/24/2017
Kamada Ltd. (KMDA) Release: Company Announces Positive Scientific Advice Response From The EMA Focused On Alpha-1 Antitrypsin IV For Treatment Of Acute Graft-Versus-Host Disease 1/23/2017



//-->